Drug intelligence / Profile preview

fluoxetine + budesonide

Development stage: Unknown
Lead developer: Drugs for Neglected Diseases initiative
Modality: Small Molecules
Administration: Oral, Inhalation

Overview

A combination of fluoxetine (an antidepressant) and budesonide (a corticosteroid) that has been investigated for COVID-19 treatment. Fluoxetine inhibits viral replication by preventing viral entry into cells and may have immunosuppressive activity, while budesonide provides anti-inflammatory effects in the lungs. This combination targets both the viral replication stage and the inflammatory stage of COVID-19 infection.

Targets

GR (Glucocorticoid receptor)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on fluoxetine + budesonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoxetine + budesonide.

Explore the full profile